Welcome to BioSeeker Group!

New Concepts in Cancer Therapeutics

Additional Information

Published Date Dec 30, 2005
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 269
PDF Fact Sheet View Fact Sheet for the report New Concepts in Cancer Therapeutics in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$2,450.00

Quick Overview

There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 20 years ago. Many of the new classes of agents....

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to New Concepts in Cancer Therapeutics.

    To find out more about New Concepts in Cancer Therapeutics, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that New Concepts in Cancer Therapeutics is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Introduction

In the world there are close to 25 million people living with cancer today, a figure that will probably increase to around 30 million people by 2020 .This publication is one of the most extensive studies of novel concepts for fighting cancer.

Scope of this report

  • Global cancer trends
  • Global pipeline overview and clinical trial analysis
  • Current treatment of major cancer indications
  • Strategy and progress on new anticancer targets and drugs
  • Evolving screening technologies


Research and analysis highlights

There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 20 years ago. Many of the new classes of agents, however, are predicted to work in only small subpopulations of patients, target unconventional aspects of tumour development and interact with other agents in an unpredictable manner. How can research and clinical trials be re-designed to accommodate the new features of targeted anticancer drugs? This publication reports on more than 100 companies and close to a 100 different anticancer drugs, where of 20 are new to the world in general.

Key reasons to read this report

  • Find out where the cancer market is going
  • Current status on drugs available to fight major cancer indications
  • Discover the very latest about new innovative anticancer drugs, and how they are made
  • Anticancer R&D strategies

1 Executive Summary

2 Cancer Highlights

3 Methodology

4 4.1 List of Boxes
4.2 List of Figures
4.3 List of Tables

5 Global Cancer Trends
5.1 The Global Cancer Therapeutic Market, Drivers and Blockbuster drugs

6 Strategic Keys & Insights to the Global Cancer Pipeline
6.1 Historical FDA Approvals for Cancer Therapeutics

7 Changes in Clinical Trial Design, Endpoints & Markers
7.1 Key Source of Trial Inconsistency
7.2 Toxicity: Safety & Tolerability
7.3 Maximal Tolerated Dose
7.3.1 Dose Limiting Toxicity
7.4 Efficacy: Add-On Drug
7.5 Discussions for a shift in cancer trial design
7.5.1 Biologically defined surrogate markers
7.5.2 Molecular Profiling of Drug Targets and ’Best Fit Drugs’
7.5.3 Markers of Efficacy
7.5.4 Heterogenity; tumors & drugs
7.5.5 The risk of missing good leads is a devastating waste of property

8 Treatment regimes
8.1 Breast cancer
8.1.1 Drugs approved by FDA
8.1.2 A Shift in Standard Treatment Recommendations
8.1.3 Clinical Progress of the Established Drugs
8.1.4 Estrogen receptor modulators
8.1.5 Aromatase Inhibitors
8.1.6 Herceptin
8.2 Colorectal cancer
8.2.1 Capecitabine
8.2.2 Irinotecan
8.2.3 Bevacizumab
8.2.4 Oxaliplatin
8.2.5 Cetuximab
8.2.6 Levamisole
8.3 Melanoma
8.3.1 Dacarbazine
8.3.2 Cisplatin
8.3.3 Carboplatin
8.3.4 Carmustine
8.3.5 Melphalan
8.3.6 Paclitaxel
8.3.7 Tamoxifen
8.3.8 Temozolomide
8.3.9 Vinblastine/Vinorelbine
8.3.10 Virulizin
8.3.11 Melacine
8.3.12 Alfanative (Multiferon)
8.3.13 Proleukin or (Macrolin)
8.3.14 Ceplene Maxamine
8.4 Lung cancer
8.4.1 General
8.4.2 Platinum-based chemotherapy
8.4.3 Docetaxel
8.4.4 Paclitaxel
8.4.5 Vinorelbine
8.4.6 Gemcitabine
8.4.7 Gefitinib
8.5 Leukemia
8.5.1 ALL
8.5.2 AML
8.5.3 CML
CML R&D
8.5.4 Prostate cancer
8.5.4.1 Zoladex, Goserelin
8.5.4.2 Finasteride, Proscar, Propecia
8.5.4.3 Progress Analysis: Casodex, (R)-bicalutamide
8.6 The Anticancer Pipeline: General trends
8.6.1 Therapeutic Antibodies
8.6.2 Immunotherapies
8.6.3 Gene therapies
8.6.3.1 Viral vectors
8.6.3.2 Synthetic Delivery Systems
8.6.4 Vascular targeting & Antiangiogenesis
8.6.5 Protein kinase inhibitors
8.6.5.1 CDK Inhibitors
8.6.5.2 Other Types of Protein Kinase Inhibitors
8.6.6 Apototic inducers
8.6.7 Multipathway Regulators
8.6.8 Endothelin Receptor Antagonists
8.6.9 Inflicting DNA Synthesis
8.6.10 Targeting Hormone Action

9 Progress on New Drugs and Targets
9.1 Hypoxic Activated Prodrug
9.2 New Kinase Inhibitors
9.2.1.1 Progress Analysis: SKI-606
9.2.1.2 Progress Analysis: BMS-354825
9.2.2 Aurora Kinase Inhibitors
9.2.2.1 Aurora in Clinical Development
9.2.3 New CDK Inhibitors
9.2.3.1 Progress Analysis: CYC202
9.2.3.2 Progress Analysis: BMS-387032
9.3 Wanted: Insulin-like Growth Factor 1 Receptor
9.4 Novel Apoptosis Inducers – The Killer?
9.4.1.1 Progress Analysis: Programmed Cell Death 1 Drug
9.4.1.2 Progress Analysis: Programmed Cell Death 8 Drug
9.5 Novel Taxanes
9.6 PEG-camptothecin Conjugates
9.7 Hitting on Kinesins
9.7.1.1 Progress Analysis: SB-715992
9.8 Antiangiogenesis through Targeting Cell Adhesion
9.8.1.1 Progress Analysis: Exherin
9.8.1.2 Progress Analysis: N-cadherin antagonists
9.8.1.3 Progress Analysis: OB-cadherin antibodies
9.8.1.4 Progress Analysis: VE-cadherin antibodies
9.9 Molecular Target of Rapamycin
9.10 Other New Interesting Anticancer Drug Targets
9.10.1.1 Progress Analysis: n-CoDeR anti Angiomotin
9.10.1.2 Progress Analysis: Chemokine, ELC/CCL19
9.10.1.3 Progress Analysis: LY 2275796
9.10.1.4 Progress Analysis: Anti-CD32 MAb
9.10.1.5 Progress Analysis: HAS2 inhibitor
9.10.1.6 Progress Analysis: MDX-1307
9.10.1.7 Progress Analysis: Ubiquitin modulators

10 Novel Screening Technologies
10.1 The Omics Era
10.2 Genomics Information Providers
10.3 Selection of Targets in Drug Discovery
10.3.1 Therapeutic Value, Essential in Lead Optimization
10.3.2 Virtual Library Screening
10.3.3 Drug Discovery through Three-Dimensional Information
10.3.4 In Silico Evaluation of ADME-Tox/Efficacy
10.3.4.1 Allosteric Binding Sites
10.3.4.2 New Family of Membrane-Bound Serine Proteases
10.4 Power in Combinatorial Synthesis
10.4.1 From High- Throughput Screening To High-Content Screening
10.4.1.1 Cell based approaches vs Biochemical screening
10.4.2 Aptamer In Drug Discovery
10.4.3 Cytostatic Agents, A Need For Longer-Term Model System
10.4.4 Explanation to The Anti-Angiogenetic Clinical Failures
10.5 A Need to Develop New Mouse Models
10.5.1 RNA interference-mediated inhibition
10.6 Progress in Assay Development

11 Selected Company profiles
11.1.1 Adventrx Pharmaceuticals Inc
11.1.2 Amgen Inc
11.1.3 AVI BioPharma
11.1.4 Bioaccelerate Inc
11.1.5 Cancer Research Technology
11.1.6 Celgene Corporation
11.1.7 F Hoffmann-La Roche Ltd
11.1.8 GlaxoSmithKline Plc
11.1.9 Igeneon AG
11.1.10 Johnson & Johnson
11.1.11 Novartis International AG
11.1.12 Onyvax Ltd
11.1.13 Pfizer Inc

12 Disclaimer
13 Drug Index
14 Company Index

4.1 List of Boxes
Box 1: Defining Limiting Toxicity
Box 2: Critical Risk Factors for Development of Melanoma
Box 3: Major Treatment Regimes
Box 4: CLL Staging System
Box 5: General Structure for Treatment of AML
Box 6: Difficulties Facing Anti-angiogenesis
Box 7: New Target - EGF Like Domain
Box 8: Kinesin Development Patents
Box 9: Competitive Patents to those of Adherix
Box 10: Important Targets in Cancer Drug Discovery
Box 11: DS Modelling Components

4.2 List of Figures
Figure 1: Growth of Cancer Therapeutic Companies, 1985-2005
Figure 2: The Global Cancer Pipeline by 2005
Figure 3: Summarized Description of Colon Cancer Development and Clinical Outcome
Figure 4: Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways
Figure 5: Phases in the drug discovery process
Figure 6: Analysis of Risk/Return for new chemical entities. Marketed between the years 1975 to 1984.
Figure 7: ADME/Tox Evaluation Process

4.3 List of Tables
Table 1: Anti-cancer Agents with Blockbuster Status
Table 2: The Ten Highest Cancer Indications in Number of Drugs in Development
Table 3: Line of Current Cancer Therapeutics
Table 4: Cancer Therapeutic Strategies of Specific Interest
Table 5: Novel Approaches to Cancer Therapy
Table 6: Key Parameters for Designing a Phase II Study
Table 7: Available BioMarkers
Table 8: Clinical Practise Guidelines
Table 9: 5-year Survival Rate in CRC
Table 10: Risk Factors for Colon Cancer Development6
Table 11: Summary of Colorectal Cancer Regimens
Table 12: Summary of Chemotherapy Drugs
Table 13: Definition and Description of Stages of Melanoma
Table 14: Prognosis of the 4 Stages of Malignant Melanoma
Table 15: Approved Cytotoxic Drugs for Treatment of Melanoma
Table 16: Prostate Clinical Studies
Table 17: Summary of Strategies Enhancing Antibody Function
Table 18: Therapeutic Interventions for Exploiting Differences Between Normal and Tumor
Endotheliu
Table 19: CDK Inhibitors
Table 20: Other Kinase Inhibitors in Development
Table 21: Common Gene/Protein Defects in Apoptotic Pathways
Table 22: Overview of Apoptosis Targets in Development
Table 23: Key Industry Releated R&D
Table 24: Hormone Modulating Drugs
Table 25: AQ4N Research
Table 26: Src & Abl Related R&D Projects
Table 27: Companies with Interest in Aurora Kinase
Table 28: CDK inhibitors Drugs under Development
Table 29: Inhibitors of IGF and IGF-R in Development
Table 30: Overview of Apoptosis Drugs – Preclinical to Marketed
Table 31: Biological Drugs as Apoptotic Inducers
Table 32: Selected Competing Taxane Drugs
Table 33: Selection of Camptothecin Derivates
Table 34: Kinesin Related R&D Projects
Table 35: Antiangiogenesis Compounds Targeting Cell Adhesion
Table 36: Other Cell Adhesion Related Projects
Table 37: Selected Rapamycin Analogs
Table 38: New Anticancer Drug Target Emerging 2004-2005
Table 39: Relative Strengths and Weaknesses of Tools used in Structural Proteomics
Table 40: Selected Proteomics Drug Discovery Companies
Table 41 Biochemical Assay Methods that are Used for High-Throughput Screening

- Adventrx Pharmaceuticals Inc
- Amgen Inc
- AVI BioPharma
- Bioaccelerate Inc
- Cancer Research Technology
- Celgene Corporation
- F Hoffmann-La Roche Ltd
- GlaxoSmithKline Plc
- Igeneon AG
- Johnson & Johnson
- Novartis International AG
- Onyvax Ltd
- Pfizer Inc

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to New Concepts in Cancer Therapeutics.
    To find out more about New Concepts in Cancer Therapeutics, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that New Concepts in Cancer Therapeutics is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Cancer Peptides: From First-in-Class to Best-in-Class?
In-depth pipeline analytics of peptide drugs in oncology showing you where the Competition is, What is first-in-class and Is First-in-Class the Best-in-Class?, Indication expansion opportunities and much more Learn More


The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave
The blockbuster drugs Rituxan, Avastin, and Erbitux have change the way the industry looks upon antibody treatment of cancer in the same way that Taxol changed the way pharmaceutical companies look at the possibilities in the field of cancer therapeutics. Learn More

Other selected research from the 'R&D' category:


Target Atlas in Breast Cancer: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More


Toll-Like Receptor Signaling Pathway in Cancer Drug Pipeline Update
BioSeeker Group have identified 238 companies plus partners who are today developing 301 Toll-like Receptor signaling pathway targeting drugs in 996 developmental projects in cancer across 177 different targets. In addition, there are 6 suspended drugs and another 110 drugs where development has been ceased. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Breast Cancer, Lymphoma and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lymphoma and by the mechanism/target/effect of Angiogenesis. Learn More


IL-3 Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 257 companies plus partners who are today developing 339 IL-3 pathway targeting drugs in 1225 developmental projects in cancer across 164 different targets. In addition, there are 4 suspended drugs and another 131 drugs where development has been ceased. Learn More

Other selected research from the 'Line of Treatment' category:


Strategic Outlook on Protein Kinase Inhibitors in Oncology
A strategic outlook on protein kinase inhibitors in oncology. Including targets, indictions and competitive assessment. Learn More


Protein Kinase Inhibitors in Oncology Drug Pipeline Update
BioSeeker Group have identified 462 companies plus partners who are today developing 831 PKI drugs in 2912 developmental projects in cancer across 296 different targets. In addition, there are 5 suspended drugs and another 459 drugs where development has been ceased. Learn More